Breast Cancer Locator Cuts Positive Margins in Trial

Cairn Surgical's investigational device showed lower positive margin and re-excision rates than wire localization in a 418-patient study.

Updated on Nov. 10, 2026 in Cancer

Breast Cancer Locator Cuts Positive Margins in Trial

Cairn Surgical reported that its investigational Breast Cancer Locator system reduced positive margin rates compared with wire localization in breast-conserving surgery. The pivotal trial, published in Annals of Surgical Oncology, enrolled 418 patients.

Why it matters

Positive margins often require repeat surgery, so a device that reduces them could spare patients a second operation. The results are from an investigational device that is not yet available for routine clinical use.

The trial reported positive margin rates of 14% for the device versus 21% for wire localization, and re-excision rates of 13% versus 20%. Subgroup results showed DCIS positive margins of 21% vs. 53% and invasive lobular carcinoma margins of 9% vs. 26%, with long-term outcomes and broader generalizability still to be established.

The players

Cairn Surgical

Cairn Surgical is the company developing the investigational Breast Cancer Locator system.

The details

The Breast Cancer Locator uses supine breast MRI to build a 3D interactive view of the tumor, and a patient-specific 3D-printed form lets surgeons place bracketing wires around the resection volume during surgery. The trial included 44 surgeons at 23 sites across the U.S., Canada, the U.K., and Austria, and both groups had comparable safety profiles.

Timeline

  1. November 10, 2026: Cairn Surgical highlighted results of the Breast Cancer Locator trial.

Health Landscape

The Breast Cancer Locator is positioned as an alternative to wire localization, the long-standing method for guiding breast-conserving surgery. If confirmed in broader use, the approach could shift how surgeons localize tumors before lumpectomy.

For patients facing breast-conserving surgery, a localization method with fewer positive margins could mean a lower chance of needing a second operation. The device is still investigational, so current treatment decisions rest on approved methods.

The takeaway

Patients considering breast-conserving surgery can ask their surgical team which localization methods are available and what margin outcomes their center achieves. Investigational devices are not yet standard care.

Further reading

Explore more on Cancer research and treatment developments.

Source note: This article includes information reported by AuntMinnie.